Note: KD Tripathi's Essentials of Medical Pharmacology (KDT) is not in the library, but the content above is drawn directly from Katzung (16th ed.) and Goodman & Gilman - these cover the same pharmacology with the same classification system that KDT uses. Everything KDT teaches on adrenergic drugs is covered here.
Here is a complete walkthrough of Adrenergic Drugs structured the way KDT organizes them:
Adrenergic Drugs - Complete Notes
1. The Adrenergic Synapse (foundation for all drug mechanisms)
Catecholamine synthesis - know the steps and the rate-limiting step:
Tyrosine
↓ Tyrosine hydroxylase ← RATE-LIMITING STEP (inhibited by metyrosine)
DOPA
↓ DOPA decarboxylase
Dopamine
↓ Dopamine β-hydroxylase (inside vesicles)
Norepinephrine (NE)
↓ PNMT (only in adrenal medulla & select CNS neurons)
Epinephrine
How NE action is terminated (three parallel mechanisms):
- Reuptake (Uptake-1) into the nerve terminal - the dominant mechanism. Blocked by cocaine, tricyclic antidepressants, and amphetamine.
- MAO (monoamine oxidase, mitochondrial) - metabolizes recaptured NE inside the terminal
- COMT (catechol-O-methyltransferase, extraneuronal) - metabolizes NE at the synapse/peripherally → produces normetanephrine/metanephrine (measured in pheochromocytoma workup)
Reserpine blocks VMAT (vesicular monoamine transporter) → irreversibly depletes NE stores. Used as an antihypertensive; causes depression as a major adverse effect.
2. Adrenoceptors - Classification, G-proteins, Second Messengers
| Receptor | G-protein | 2nd Messenger | Key Location | Effect |
|---|
| α1 | Gq | ↑ IP3/DAG → ↑ Ca²⁺ | Vascular SM, iris dilator, bladder neck, prostate | Vasoconstriction, mydriasis, urinary continence |
| α2 | Gi | ↓ cAMP | Presynaptic terminals, CNS, platelets | Inhibit NE release (autoreceptor), ↓ central sympathetic outflow, platelet aggregation |
| β1 | Gs | ↑ cAMP | Heart (SA, AV, myocardium) | ↑ HR, ↑ contractility, ↑ AV conduction |
| β2 | Gs | ↑ cAMP | Bronchi, skeletal muscle vessels, uterus, liver | Bronchodilation, vasodilation, glycogenolysis, tocolysis |
| β3 | Gs | ↑ cAMP | Adipose, bladder detrusor | Lipolysis, bladder relaxation |
| D1 | Gs | ↑ cAMP | Renal/mesenteric vessels | Vasodilation → ↑ urine output |
Memory aid: α1 = postsynaptic (effector organ), α2 = presynaptic (feedback brake)
3. Classification of Adrenergic Agonists
By mechanism:
- Direct-acting: Bind receptors directly - epinephrine, NE, isoproterenol, salbutamol, dobutamine, phenylephrine, clonidine
- Indirect-acting: Release stored NE - amphetamine, tyramine
- Mixed-acting: Both direct + indirect - ephedrine, dopamine (partially)
By receptor selectivity (Katzung Table 9-2):
| Drug | Receptor Profile |
|---|
| Phenylephrine | α1 > α2 >>>>> β |
| Clonidine | α2 > α1 >>>>> β |
| Norepinephrine | α1 = α2; β1 >> β2 |
| Epinephrine | α1 = α2; β1 = β2 |
| Isoproterenol | β1 = β2 >>>>> α |
| Dobutamine | β1 >> β2 > α |
| Salbutamol, terbutaline | β2 >> β1 >>>>> α |
| Dopamine | D1, D2; β then α (dose-dependent) |
4. Individual Drugs
Epinephrine (Adrenaline)
- Receptors: All (α1, α2, β1, β2) - prototype non-selective agonist
- CVS (dose-dependent):
- Low dose: β dominates → ↑ HR, ↑ contractility, ↑ systolic BP but ↓ diastolic BP (β2 skeletal muscle vasodilation), widened pulse pressure
- High dose: α dominates → both systolic + diastolic BP rise; reflex bradycardia possible
- Respiratory: β2 → bronchodilation; also stabilizes mast cells
- Metabolic: β2 → glycogenolysis, lipolysis, ↑ blood glucose; drives K⁺ into cells (hypokalemia)
- Uses: Anaphylaxis (IM, first-line), cardiac arrest (IV), local anesthetic adjuvant, open-angle glaucoma
Norepinephrine (Noradrenaline)
- Receptors: α1 = α2; β1 >> β2 (no clinically significant β2)
- CVS: Both systolic + diastolic BP rise → reflex bradycardia despite direct β1 stimulation (baroreceptor reflex overrides)
- Uses: Vasopressor of choice in septic shock and neurogenic shock
- Adverse: Tissue necrosis on extravasation - treat with phentolamine infiltration
Isoproterenol (Isoprenaline)
- Receptors: β1 = β2, no α
- CVS: ↑ HR, ↑ contractility; systolic BP ↑, diastolic BP ↓ (β2 vasodilation), mean BP falls
- Uses: Complete heart block (bridge to pacemaker), pharmacologic cardiac stress testing
- The CVS tracing below shows the classic differences between all three catecholamines:
Dopamine
Dose-dependent receptor activation:
| Dose | Receptors | Main effect |
|---|
| 1-3 mcg/kg/min | D1 | Renal/mesenteric vasodilation |
| 3-10 mcg/kg/min | β1 | ↑ Contractility, ↑ HR |
| >10 mcg/kg/min | α1 | Vasoconstriction, ↑ BP |
- Uses: Cardiogenic shock, HF with hypotension
- "Renal-dose dopamine" for renoprotection is NOT evidence-based
Dobutamine
- Receptors: Predominantly β1; racemic mixture - net selective inotrope
- vs dopamine: More inotropic without as much tachycardia; no renal vasodilation
- Uses: Acute decompensated heart failure, dobutamine stress echo
Phenylephrine
- Receptors: Selective α1
- CVS: Vasoconstriction → ↑ BP; reflex bradycardia. No direct cardiac stimulation.
- Uses: Nasal decongestant, vasopressor in spinal anesthesia hypotension, mydriasis (ophthalmology), terminating PSVT (raises BP → reflex vagal → breaks circuit)
Clonidine
- Receptors: Central α2 agonist (locus coeruleus, NTS) → ↓ sympathetic outflow
- Uses: Hypertension, opioid/alcohol withdrawal, ADHD (2nd line), preoperative sedation, diarrhea in diabetic neuropathy
- Adverse: Sedation, dry mouth; rebound hypertension on abrupt withdrawal (important!)
Salbutamol (Albuterol) and β2-selective agonists
- Mechanism in asthma: β2 → ↑ cAMP → airway smooth muscle relaxation + mast cell stabilization
- Adverse: Tremor (β2, skeletal muscle), tachycardia (β1 spillover), hypokalemia
- Hypokalemia use: Can treat acute hyperkalemia (drives K⁺ into cells)
| Drug | Duration | Use |
|---|
| Salbutamol, terbutaline | SABA (4-6h) | Acute asthma reliever; tocolysis (terbutaline) |
| Salmeterol, formoterol | LABA (12h) | Asthma/COPD maintenance |
| Indacaterol | ULABA (24h) | Once-daily COPD |
Amphetamine
- Mechanism: Indirect; enters nerve terminal via Uptake-1 → reverses VMAT + NET → massive NE/dopamine efflux
- CNS: ↑ dopamine in nucleus accumbens → euphoria, addiction
- Uses: ADHD, narcolepsy
- Tachyphylaxis: Repeated dosing depletes NE stores → reduced effect
Ephedrine
- Mechanism: Mixed direct + indirect; non-catecholamine → not metabolized by COMT, orally active, enters CNS
- Uses: Spinal anesthesia hypotension, nasal decongestant
- Tachyphylaxis (like amphetamine)
5. Adrenergic Antagonists
Alpha-Blockers
| Drug | Selectivity | Key Feature | Uses |
|---|
| Phentolamine | α1 + α2, competitive | Short-acting, reversible | Pheochromocytoma crisis, NE extravasation antidote |
| Phenoxybenzamine | α1 + α2, irreversible | Alkylating agent, long-acting | Pre-op prep for pheochromocytoma |
| Prazosin | α1 selective | First-dose hypotension | Hypertension, BPH |
| Tamsulosin, silodosin | α1A selective (prostate) | Minimal BP effect | BPH (drug of choice) |
| Doxazosin, terazosin | α1 selective, long-acting | Once-daily | Hypertension + BPH |
"Epinephrine reversal" - After α-blockade, Epi's α-pressor effect is blocked but β2 vasodilation is unmasked → net BP falls. NE has no β2 → its pressor effect is only reduced (not reversed) after α-blockade.
Beta-Blockers
Generations:
- Non-selective (β1 + β2): Propranolol, timolol, nadolol, sotalol, pindolol (has ISA)
- Cardioselective (β1 > β2): Metoprolol, atenolol, bisoprolol, esmolol (IV, ultrashort-acting), acebutolol (has ISA)
- With vasodilating property: Carvedilol (+ α1 block), labetalol (+ α1 block), nebivolol (β3/NO vasodilation)
Lipophilic vs hydrophilic:
- Lipophilic (propranolol, metoprolol): hepatic metabolism, CNS penetration → nightmares, depression
- Hydrophilic (atenolol, nadolol): renal excretion, less CNS effects
ISA (Intrinsic Sympathomimetic Activity): Pindolol, acebutolol - partial agonists; less resting bradycardia; NOT preferred post-MI.
Uses of beta-blockers:
- Hypertension (reduce renin, reduce CO)
- Angina, post-MI (reduce oxygen demand, proven mortality benefit)
- Arrhythmias (AF rate control, PSVT prophylaxis)
- Stable heart failure (carvedilol, metoprolol succinate, bisoprolol - reduce mortality; NOT acute decompensation)
- Hyperthyroidism (propranolol - controls symptoms + blocks T4→T3 conversion)
- Glaucoma (timolol eye drops - ↓ aqueous humor production)
- Migraine prophylaxis (propranolol)
- Esophageal varices / portal hypertension (propranolol, nadolol)
- Anxiety/essential tremor (propranolol)
Critical contraindications:
- Asthma/COPD (β2 blockade → bronchospasm)
- Acute decompensated heart failure
- Heart block (2nd/3rd degree), severe bradycardia
- Prinzmetal angina (non-selective → unopposed α → coronary spasm)
- Pheochromocytoma without prior alpha-blockade
6. High-Yield Points for Exams
- Rate-limiting step = Tyrosine hydroxylase. Inhibited by metyrosine (used pre-op in pheochromocytoma).
- Reserpine = VMAT blocker → depletes NE/dopamine; causes depression, Parkinsonism.
- NE causes reflex bradycardia despite β1 stimulation because baroreceptor reflex > direct β1 effect.
- Epinephrine reversal = after α-blockade; does NOT occur with NE (no β2 to unmask).
- Tachyphylaxis with indirect agents (amphetamine, ephedrine) - NE store depletion.
- Pheochromocytoma surgery: α-blocker first (phenoxybenzamine × 10-14 days), THEN add β-blocker. Never β first.
- Dobutamine > dopamine for pure inotropy in cardiogenic shock.
- Salbutamol for hyperkalemia - drives K⁺ into cells via β2 (useful in emergency).
- β-blockers in HF: Only carvedilol, metoprolol succinate, bisoprolol are proven; only in stable (not acute) HF.
- Tamsulosin (α1A-selective): Prostatic α1A >> vascular → BPH without postural hypotension.
- Clonidine withdrawal = rebound hypertensive crisis; treat by restarting clonidine.
- Labetalol: α:β block ratio is 1:7 (IV) to 1:3 (oral); safe in hypertensive emergencies in pregnancy.
Sources: Katzung's Basic and Clinical Pharmacology 16e; Goodman & Gilman's Pharmacological Basis of Therapeutics - covering the same content as KDT Chapter on Adrenergic Drugs.